Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH006 Combination Therapy in Advanced Hepatocellular Carcinoma
NCT07392866Phase 3Not yet recruiting
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SH006 in hepatocellular carcinoma (HCC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SH006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07392866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392866.